

# FY 2013-2014 CU Tech Transfer Performance Metrics



University of Colorado

Boulder | Colorado Springs | Denver | Anschutz Medical Campus

**TECHNOLOGY TRANSFER OFFICE**

**Kate Tallman**

**Associate Vice President for  
Technology Transfer**

**[kate.tallman@cu.edu](mailto:kate.tallman@cu.edu)**

# Shifting Landscape of CU Technology Transfer

- There is a nationwide shift in emphasis towards “innovations” more broadly than patentable discoveries from universities.
- Faculty engaged in the university research enterprise are preparing for a shift away from exclusive reliance on federal government funding.
- CU TTO is responding to these shifts by engaging with leadership on all campuses on new visions to engage with industry collaborators to bring more innovations to market.
- The shift in emphasis requires TTO to build capacity to add value to a wide variety of innovations that will be brought to market through diverse channels

# Dashboard Look at FY 2013-2014

- ↑ Invention disclosures [maintained consistent level of invention disclosures, representing strong engagement with faculty]
- ↓ US patent applications [increasing investment in more focused IP portfolio]
- ↑ Exclusive licensing transactions [economic recovery in Colorado and nationwide drove near record license agreements]
- ↑ Nonexclusive licensing transactions [increased focus on developing nonexclusive licenses for biological materials research tools]
- Start-ups [9 new startups distributed throughout the CU system]
- POC program [final round of state BDEG program prior to the merger with Advanced Industries Accelerator, working on a new process for non-bio AIA development and review]
- ↑ Equity liquidations [proceeds from 4 companies with liquidity events prior to or during the 2013-2014 fiscal year]
- ↓ Overall revenue [running royalties build slowly on maturing portfolio, 2012 monetization cuts royalty totals by 1/3]

# Dashboard Look at FY 2013-2014

- Patent reimbursements [significant change in reimbursement structure due to increased speculative patent investment]
- ↑ Integration with University programs [support for industry research initiatives is of growing importance and represents a major priority]
- Support from the business community [vibrant activity around accelerators and “gazelle” companies takes focus away from early stage university spinouts, TTO continues to make the case that research-based innovation is an important feeder to our ecosystem]
- TTO staff [managed significant staff transition and built a well functioning team to get deals done and build the pipeline of opportunities]

Net, TTO capitalized on many new opportunities that came with the economic recovery.

# CU Technology Transfer Over the Past Nine Years

Fiscal Year	05-6	06-7	07-8	08-9	09-10	10-11	11-12	12-13	13-14
Invention disclosures	200	255	238	261	233	250	226	238	<b>250</b>
New patent filings	72	100	90	104	127	126	116	115	<b>90</b>
Follow-on patent filings	164	241	246	198	215	228	205	243	<b>227</b>
Total options/licenses	59	80	61	63	59	51	49	45	<b>57</b>
Exclusive options/licenses	38	41	45	51	41	40	34	29	<b>43</b>
License revenue in \$MM*	21.4	23.9	6.1	4.4	2.4	3.9	32.8	16.5	<b>4.3</b>
Start-up companies	10	10	11	11	9	11	10	8	<b>9</b>

\*Does not include revenue derived from legal settlements which in FY05-6 amounted to \$0FT.7M, and in FY06-07 \$1.3M.

# Companies Created in FY 2013-2014 Based on CU Intellectual Property

<b>Company</b>	<b>Campus</b>	<b>Technology</b>
<b>BioElectric</b>	<b>Denver</b>	<b>Bioelectrochemical water reconditioning for oil and gas production</b>
<b>Clear Creek Networks</b>	<b>Boulder</b>	<b>Flexible, secure networking communications for electrical grids</b>
<b>EdTRENX</b>	<b>Boulder</b>	<b>Software platform supporting individualized curricula and student learning objectives</b>
<b>EnteroTrack</b>	<b>Anschutz</b>	<b>Non-Invasive diagnosis and monitoring of esophageal disease</b>
<b>Galaxy Ophthalmics</b>	<b>Anschutz</b>	<b>Implantable medical device to help prevent loss of vision resulting from glaucoma</b>
<b>Mile High Ophthalmics</b>	<b>Anschutz</b>	<b>Ophthalmic device for enhanced precision in cataract surgery</b>
<b>OcuTherix</b>	<b>Anschutz</b>	<b>Non-invasive glaucoma treatment device</b>
<b>Ocugen</b>	<b>Anschutz</b>	<b>Novel biotherapeutics to treat eye diseases</b>
<b>Recreo Pharma</b>	<b>Boulder</b>	<b>Resistance-modifying agents to combat antibiotic resistance</b>

# Start-up Company Sustainability and Capital Raised

- In the last 20 years, 141 companies have been formed based on CU intellectual property.
- Of these, 113 are operational as either stand alone or subsidiary/merged companies.
- CU IP has been relicensed from 10 of the 27 discontinued companies.
- 96 of the 113 continuing companies have operations in Colorado.
- 19 have received seed investment from TTO's convertible debt program.
- Companies started from CU IP have raised ~\$6.2B in capital from federal and state grants, TTO, angel, venture capital, acquisition and IPO sources.

# CU IP and Licensing Portfolio at a Glance (as of 07/01/2014)

- Total U.S. Patents in force: 402
- Total U.S. Patents in prosecution: 344
- Exclusive Licenses in good standing: 182
- Non-Exclusive Licenses in good standing: 197
- Bio Licenses in good standing: 225
- Non-Bio Licenses in good standing: 154